Short-term Efficacy and Safety of a Latanoprost/Carteolol Fixed Combination Switched From Concomitant Therapy to in Patients With Primary Open-angle Glaucoma or Ocular Hypertension

Purpose: We prospectively investigated the efficacy and safety of switching from concomitant latanoprost and carteolol hydrochloride (CH) to a latanoprost/carteolol fixed combination (LCFC) in patients with primary open-angle glaucoma or ocular hypertension. Patients and Methods: A total of 43 patients (43 eyes) who were using latanoprost (once daily in the evening) and CH (once daily in the morning) concomitantly were switched to LCFC (once daily in the morning) with no washout interval. The primary efficacy endpoint was change in intraocular pressure (IOP) between baseline (before switching) and 1 and 3 months after switching. Systemic blood pressure and pulse rate, corneal epithelial defects, and tear film break-up time (TBUT) were also compared before and 1 and 3 months after switching. A questionnaire was administered 1 month after switching to investigate ocular comfort and treatment preferences. Adverse reactions and dropouts were recorded. Results: There was no significant difference in IOP after switching to LCFC (15.0±2.6, 15.1±2.4, and 15.0±2.4 mm Hg at baseline and at 1 and 3 months, respectively). There was a significant decrease in corneal epithelial defects and significant increase in TBUT, without significant changes in systemic blood pressure or pulse rate. Three patients (7.3%) preferred concomitant latanoprost and CH; 33 (80.5%) preferred the LCFC. One patient each (9.3%) discontinued treatment because of foreign body sensation, blepharitis, increased IOP, or loss to follow-up. Conclusions: Switching from concomitant latanoprost and CH to LCFC led to similar IOP control with good safety and patient acceptance, at least in the short term.

• Publication year

  2018

• Venue

  Journal of glaucoma

• Publication date

  2018-12-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1097/IJG.0000000000001091PMID 30234748
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Randomized, Controlled, Phase 3 Trials of Carteolol/Latanoprost Fixed Combination in Primary Open-Angle Glaucoma or Ocular Hypertension.

  2016cited by this paper
• Latanoprost for open-angle glaucoma (UKGTS): a randomised, multicentre, placebo-controlled trial.

  2015cited by this paper
• Ocular hypotensive effect and safety of travoprost 0.004%/timolol maleate 0.5% fixed combination after change of treatment regimen from β-blockers and prostaglandin analogs

  2012cited by this paper
• Assessment of ocular hypotensive effect and safety 12 months after changing from an unfixed combination to a latanoprost 0.005% + timolol maleate 0.5% fixed combination

  2012cited by this paper
• [Long-acting carteolol hydrochloride 2% ophthalmic solution phase IV study--investigation of the effectiveness, safety and plasma concentration].

  2010cited by this paper
• Tolerability, quality of life, and persistency of use in patients with glaucoma who are switched to the fixed combination of latanoprost and timolol

  2007cited by this paper
• [Ocular hypotensive effect of 1% carteolol long-acting eye drops--a double-masked, randomized phase III study in ocular hypertension or primary open-angle glaucoma patients comparing long-acting carteolol eye drops vs. current product].

  2007cited by this paper
• A 12 week study comparing the fixed combination of latanoprost and timolol with the concomitant use of the individual components in patients with open angle glaucoma and ocular hypertension

  2004cited by this paper
• Short term efficacy and safety in glaucoma patients changed to the latanoprost 0.005%/timolol maleate 0.5% fixed combination from monotherapies and adjunctive therapies

  2004cited by this paper
• Comparison of the Short-Term Effects on the Human Corneal Surface of Topical Timolol Maleate With and Without Benzalkonium Chloride

  2003cited by this paper
• [Efficacy and safety of long-acting carteolol 1% once daily. A double-masked, randomized study].

  2003cited by this paper
• Ocular hypotensive efficacy and safety of once daily carteolol alginate

  2001cited by this paper
• Cytotoxicity of potential ocular permeation enhancers evaluated on rabbit and human corneal epithelial cell lines.

  2001cited by this paper
• Report of the National Eye Institute/Industry workshop on Clinical Trials in Dry Eyes.

  1995cited by this paper
• Long-term morphologic effects of antiglaucoma drugs on the conjunctiva and Tenon's capsule in glaucomatous patients.

  1989cited by this paper

• Topical glaucoma medications - Clinical implications for the ocular surface.

  2022cites this paper
• Topical Medication Therapy for Glaucoma and Ocular Hypertension

  2021cites this paper
• Comprehensive Pharmacology: Glaucoma

  2021cites this paper
• Comparison of the 24-h efficacy and safety of fixed combination carteolol/latanoprost and timolol/latanoprost in patients with primary open-angle glaucoma and ocular hypertension: a prospective crossover study

  2021cites this paper
• OPTH_A_240425 1207..1214

  2020cites this paper
• Balancing treatments for patients with systemic hypertension and glaucoma

  2020cites this paper
• Short-Term Efficacy and Safety of Switching from a Latanoprost/Timolol Fixed Combination to a Latanoprost/Carteolol Fixed Combination

  2020cites this paper